Clene Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
CLNN$4.41+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(751) | $(11,080) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 404 | 420 |
| Non-cash lease expense | 133 | 122 |
| Change in fair value of common stock warrant liabilities | (2,510) | 1,309 |
| Change in fair value of derivative liabilities | (1,147) | — |
| Change in fair value of Clene Nanomedicine contingent earn-out liability | — | (53) |
| Change in fair value of Initial Stockholders contingent earn-out liability | — | (7) |
| Stock-based compensation expense | 1,947 | 2,013 |
| Accretion of debt discount | 237 | 367 |
| Non-cash interest income on marketable securities | — | (81) |
| Non-cash interest expense on notes payable | 12 | 91 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 64 | 79 |
| Inventory | 30 | — |
| Prepaid expenses and other current assets | (931) | (428) |
| Accounts payable | 173 | 141 |
| Accrued liabilities | (2,521) | 185 |
| Operating lease obligations | (151) | (160) |
| Net cash used in operating activities | (5,011) | (7,082) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | — | (6,168) |
| Proceeds from maturities of marketable securities | — | 6,250 |
| Purchases of property and equipment | — | (11) |
| Net cash provided by investing activities | — | 71 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | 2,673 | — |
| Payments of finance lease obligations | — | (19) |
| Net cash provided by (used in) financing activities | 2,673 | (19) |
| Effect of foreign exchange rate changes on cash and restricted cash | 15 | (59) |
| Net decrease in cash, cash equivalents and restricted cash | (2,323) | (7,089) |
| Cash, cash equivalents and restricted cash – beginning of period | 12,213 | 28,879 |
| Cash, cash equivalents and restricted cash – end of period | $9,890 | $21,790 |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $9,832 | $21,732 |
| Restricted cash | 58 | 58 |
| Cash, cash equivalents and restricted cash | $9,890 | $21,790 |
| Supplemental cash flow information: | ||
| Cash paid for interest expense | $359 | $784 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.